Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00035516 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of Epothilone Analog BMS-247550 in Patients With Non-Small Cell Lung Cancer Who Have Failed First Line Platinum Based Chemotherapy
A Phase 2 study of Carcinoma, Non-Small Cell Lung, sponsored by R-Pharm.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Study locations
NCT00035516 is a Phase 2 study of Carcinoma, Non-Small Cell Lung that has completed, run by R-Pharm. The trial reports 16 study locations across 14 states.
The verdict
NCT00035516, a Phase 2 study of Carcinoma, Non-Small Cell Lung, has completed, sponsored by R-Pharm.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16
- Study locations
Study Summary
The purpose of this clinical research study is to learn if BMS-247550 can shrink or slow the growth of the cancer in patients with non-small cell lung cancer who have failed first-line platinum based chemotherapy. The safety of this treatment will also be studied.
Conditions Studied
Interventions
- DRUG Epothilone
Study Locations (16)
Florida
- Mount Sinai Medical Center - Miami Beach
- H Lee Moffitt Cancer Center - Tampa
Tennessee
- Sarah Cannon Cancer Center - Nashville
- Vanderbilt University Med School Div of Medical Oncology - Nashville
Alabama
- University of Alabama at Birmingham - Birmingham
California
- Un of California Davis Cancer Center - Sacramento
Illinois
- Rush Presbyterian St Lukes ME - Chicago
Kentucky
- Consultants in Blood Disorders - Louisville
Louisiana
- Ochsner Cancer Institute - New Orleans
Maryland
- University of Maryland Greenbaum Cancer Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-02 |
| Est. Completion | 2004-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00035516
The ClinicalTrials.gov registry entry for NCT00035516 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is R-Pharm, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 1 intervention - of which Epothilone is the first listed.
NCT00035516 reports 16 study locations spanning 14 distinct geographic areas - top geographies include Florida, Tennessee, Alabama.
Frequently Asked Questions
What is clinical trial NCT00035516 about?
NCT00035516 is a clinical study titled "A Phase II Study of Epothilone Analog BMS-247550 in Patients With Non-Small Cell Lung Cancer Who Have Failed First Line Platinum Based Chemotherapy". The purpose of this clinical research study is to learn if BMS-247550 can shrink or slow the growth of the cancer in patients with non-small cell lung cancer who have failed first-line platinum based chemotherapy. The safety of this treatment will also be studied.
What is the current status of trial NCT00035516?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-02. Estimated completion is 2004-04.
What conditions does trial NCT00035516 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.
What interventions are being tested in trial NCT00035516?
The interventions under investigation include: Epothilone (DRUG).
Who is sponsoring clinical trial NCT00035516?
This trial is sponsored by R-Pharm, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00035516 being conducted?
This trial has 16 study locations across Alabama, California, Florida, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Non-Small Cell Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
RECRUITING · Phase 2
-
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
RECRUITING · Phase 2
-
Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy
RECRUITING · Phase 2
-
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
RECRUITING · Phase 2
-
Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC
RECRUITING · Phase 2
-
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.